AcelRx Pharmaceuticals Stock News

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX).  Such investors ar

AcelRx Pharmaceuticals, Inc. (ACRX) Management on Q4 2020 Results - Earnings Call Transcript

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 16.67% and -1.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 44.44% year over year to ($0.10), which we

REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of inno

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such in

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX).  Such investors ar

REDWOOD CITY, Calif., March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial resul

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such inv

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advi

It has been over two years since DSUVIA's approval, but AcelRx is finally starting to record some sales. The launch took longer than expected and the share price was punished. The Department of Defens

The company announced the pricing of a public stock offering.

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.